IRIS
Resteghini, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.649
AS - Asia 2.326
SA - Sud America 439
EU - Europa 343
Continente sconosciuto - Info sul continente non disponibili 121
AF - Africa 43
OC - Oceania 1
Totale 5.922
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.535
SG - Singapore 1.419
CN - Cina 451
BR - Brasile 370
VN - Vietnam 198
IT - Italia 130
HK - Hong Kong 80
GB - Regno Unito 63
CA - Canada 62
DE - Germania 43
IN - India 43
AR - Argentina 30
BD - Bangladesh 29
MX - Messico 26
FR - Francia 24
ZA - Sudafrica 16
PL - Polonia 15
ID - Indonesia 14
IQ - Iraq 14
EC - Ecuador 13
JP - Giappone 12
ES - Italia 11
PK - Pakistan 11
RU - Federazione Russa 11
VE - Venezuela 11
SE - Svezia 8
TR - Turchia 8
CO - Colombia 6
IE - Irlanda 6
KE - Kenya 6
MY - Malesia 6
PH - Filippine 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
MA - Marocco 5
NL - Olanda 5
NP - Nepal 5
SA - Arabia Saudita 5
UA - Ucraina 5
BB - Barbados 3
DZ - Algeria 3
ET - Etiopia 3
JM - Giamaica 3
JO - Giordania 3
KZ - Kazakistan 3
OM - Oman 3
PY - Paraguay 3
RO - Romania 3
TT - Trinidad e Tobago 3
AL - Albania 2
AT - Austria 2
CL - Cile 2
DO - Repubblica Dominicana 2
EG - Egitto 2
HN - Honduras 2
HR - Croazia 2
LT - Lituania 2
NI - Nicaragua 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
TN - Tunisia 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BO - Bolivia 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BW - Botswana 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
EE - Estonia 1
FI - Finlandia 1
GA - Gabon 1
GD - Grenada 1
GT - Guatemala 1
IL - Israele 1
KR - Corea 1
MG - Madagascar 1
NG - Nigeria 1
RS - Serbia 1
SI - Slovenia 1
SR - Suriname 1
UG - Uganda 1
VI - Stati Uniti Isole Vergini 1
Totale 5.802
Salva come PNG Salva come JPEG
Città #
Singapore 597
San Jose 458
Ashburn 359
The Dalles 200
Beijing 159
Shanghai 147
Council Bluffs 121
Dallas 104
Santa Clara 96
Hong Kong 73
Ho Chi Minh City 68
Los Angeles 52
New York 44
Hanoi 41
Milan 40
Phoenix 39
Buffalo 31
Seattle 30
São Paulo 28
Chicago 25
Assago 20
Montreal 20
Boardman 19
Brooklyn 19
Naples 17
Princeton 17
Atlanta 15
Rio de Janeiro 14
Warsaw 14
Mexico City 12
Tokyo 12
Brasília 11
Denver 11
Düsseldorf 11
Frankfurt am Main 11
Houston 11
Abbeville 10
Haiphong 10
Orem 10
Boston 9
Chennai 9
Johannesburg 9
Toronto 9
Charlotte 8
Louisville 8
Paris 8
San Francisco 8
Da Nang 7
London 7
Munich 7
Philadelphia 7
Stockholm 7
Belo Horizonte 6
Detroit 6
Manchester 6
Nairobi 6
Ontario 6
Quito 6
Richmond 6
Rome 6
Tashkent 6
Cincinnati 5
Cleveland 5
Curitiba 5
Miami 5
Milwaukee 5
Monza 5
Porto Alegre 5
Portsmouth 5
Ribeirão Preto 5
Baghdad 4
Baltimore 4
Biên Hòa 4
Buenos Aires 4
Bắc Ninh 4
Campinas 4
Caruaru 4
Cotia 4
Duque de Caxias 4
Eustis 4
Guayaquil 4
Laurinburg 4
Mumbai 4
Orlando 4
Poplar 4
Providence 4
Roubaix 4
Salvador 4
San Diego 4
San José 4
Secaucus 4
Addis Ababa 3
Amman 3
Amsterdam 3
Ankara 3
Bengaluru 3
Bologna 3
Bridgetown 3
Camaçari 3
Can Tho 3
Totale 3.289
Salva come PNG Salva come JPEG
Nome #
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 108
Management of loco-regionally advanced squamous laryngeal cancer in elderly patients 101
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact 99
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials 87
A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy 87
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 82
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 72
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area 72
Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events 70
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort 69
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers 67
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life 65
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports 65
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol 63
Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient 62
Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area 62
BD4QoL: A multicenter randomized trial for monitoring quality of life (QoL) by intelligent tools in head and neck cancer (HNC) survivors after curative treatment 62
Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? 61
Big Data in Head and Neck Cancer 60
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 60
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma 59
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy 59
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 59
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer 59
Health care-associated infections (HAIs) in head and neck carcinoma (HNC) patients treated with chemotherapy (CT) and/or radiotherapy (RT) 59
RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic (R/M) squamous cell carcinoma of the head and neck (SUPREME-HN) 59
Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial 58
Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting 57
Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer 57
RANK expression in EBV positive nasopharyngeal carcinoma metastasis: A ready-to-treat target? 57
A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN). 57
HEALTHCARE ASSOCIATED INFECTIONS IN HEAD AND NECK CARCINOMA PATIENTS TREATED WITH CHEMOTHERAPY AND/OR RADIOTHERAPY 56
Age related toxicity and outcome in oropharyngeal and nasoparyngeal cancer patients 56
BRAF V600E-mutated anaplastic thyroid carcinoma (ATC) and treatment with BRAF-inhibitors: Real-world data from a single-institution, still far from the cure 56
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands 56
Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up 55
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents 55
A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer 55
A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma 55
HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients 54
Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up 54
The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours 54
The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours 54
Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy 54
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients 53
An added value to Multidisciplinary Team: does a Tutor help to manage head and neck cancer patients? 53
Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? 52
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic 52
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract 52
A multicentre retrospective analysis of recurrent/metastatic (RM) nasopharyngeal cancer (NPC) from non-endemic areas: Results in the pre-immunotherapy era 52
The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer 52
Mutational profile of epithelial, non-glandular sinonasal cancers into 2 prospective clinical trials 51
Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy 50
The SINTART 1 study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton-and carbon ion-based radiotherapy (RT) integration in locally advanced operable sinonasal epithelial tumors patients (pts) 50
Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding 50
Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma 50
Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy 49
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? 49
A phase II trial of induction chemotherapy (IC), photon-, proton- and carbon ion-based radiotherapy (RT) integration in locally advanced inoperable sinonasal epithelial tumors patients (pts) 49
Locally advanced epithelial sinonasal tumors: The impact of multimodal approach 49
Prognostic role of PIK3CA and TP53 in human papillomavirus–negative oropharyngeal cancers 49
Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive head and neck squamous cell carcinoma 49
Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer 49
Transcriptomic and tumor microenvironment landscape of EBV related nasopharyngeal carcinoma in endemic and non-endemic areas 48
RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic squamous cell carcinoma of the head and neck (SUPREME-HN) 48
Refining Tumor Treatment in Sinonasal Cancer Using Delta Radiomics of Multi-Parametric MRI after the First Cycle of Induction Chemotherapy 48
A retrospective multicenter Italian analysis of the effect of longer vismodegib intake in 68 basal cell carcinoma patients who achieved clinical complete remission 48
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 48
Phase 2 study on axitinib in recurrent/metastatic salivary gland cancer of upper aerodigestive tract 47
Immunotherapy in nonendemic nasopharyngeal carcinoma: Real-world data from two nonendemic regions 47
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure 47
Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression? 46
Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients 46
Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer 45
RANK expression in EBV associated nasopharyngeal cancer metastasis in non-endemic setting: a possible immunologic pathway to be targeted? 45
Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC). 45
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 44
Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy 44
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience 44
Treatment Options for Recurrent Anterior Skull Base Tumors 44
Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma 44
Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies. 43
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? 43
Sinonasal non-glandular cancers relapsing after multimodal treatments 43
Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series 43
Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures 42
Druggable molecular targets in skin adnexal malignancies 41
Survival differences between EU and Asia for head and neck cancer: Results of the RARECAREnet-Asia collaboration 41
Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients 41
Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract (NCT02860936) 40
Site of metastatic disease influences adenoid cystic cancer (ACC) patients' outcome 40
Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib 40
Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis 40
Neoplasie testa collo 40
Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials 40
Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer: a single center experience 40
Retreatment with Vismodegib is active in progressive advanced Basal Cell Carcinoma: first report from a single-Institution experience 39
Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies 39
Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer 39
A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era 38
Totale 5.388
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.806
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.806
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024372 0 0 0 0 0 0 0 57 52 45 90 128
2024/20251.164 44 5 4 7 7 113 53 67 211 287 182 184
2025/20263.264 515 191 166 227 156 230 941 130 160 211 185 152
2026/20271.122 175 233 646 68 0 0 0 0 0 0 0 0
Totale 5.922